ETHK Labs Clarifies Regulatory Status and Market Path for Nipah Virus Detection Platforms

IVD Medical Holding Limited ( (HK:1931) ) has provided an announcement.

ETHK Labs Inc. has provided a detailed update on the regulatory status and business progress of its dual-platform solution for Nipah virus detection, developed via subsidiary Shenzhen ICXIVD Biotechnology. The solution consists of an intelligent fluorescent PCR nucleic acid detection kit designated for research use only in Mainland China and mNGS testing services offered under a Laboratory Developed Test model.

The RUO PCR kit targets professional institutions such as customs and disease control centers and currently does not pursue Class III medical device registration due to the absence of Nipah cases, which prevents required clinical trials. Meanwhile, ICXIVD’s mNGS testing services have been operating since 2022 under existing policies without needing device registration and now form a mature business line, with deployment and production of the PCR kit to be flexibly scaled according to actual demand from institutional clients.

By clarifying its regulatory pathways and application scenarios, ETHK Labs aims to enhance transparency for investors and underline the strategic rationale behind its AI healthcare upgrade. The company indicates that its Nipah virus detection capabilities are already in market use through LDT-based mNGS services, while the RUO PCR kit stands ready for broader deployment when demand and regulatory conditions allow, potentially strengthening its position in infectious disease surveillance solutions.

The most recent analyst rating on (HK:1931) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.

More about IVD Medical Holding Limited

ETHK Labs Inc., formerly known as IVD Medical Holding Limited, is a Cayman Islands–incorporated company focused on AI-driven healthcare solutions and in vitro diagnostic technologies. Through its subsidiary Shenzhen ICXIVD Biotechnology, the group develops nucleic acid detection kits and metagenomic next-generation sequencing (mNGS) testing services aimed at medical institutions, customs authorities, and disease control agencies in Mainland China.

Average Trading Volume: 4,642,058

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.82B

Find detailed analytics on 1931 stock on TipRanks’ Stock Analysis page.